PURE Bioscience, Inc.
PURE
$0.05
$0.001.17%
OTC PK
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 61.18% | 11.34% | 19.94% | -22.99% | -21.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.18% | 11.34% | 19.94% | -22.99% | -21.26% |
| Cost of Revenue | 48.74% | 13.66% | 10.07% | -17.50% | -29.18% |
| Gross Profit | 70.18% | 9.69% | 28.25% | -26.47% | -14.33% |
| SG&A Expenses | -13.49% | -22.24% | -18.22% | -17.89% | -11.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.17% | -14.55% | -13.49% | -17.45% | -15.10% |
| Operating Income | 47.42% | 28.52% | 24.79% | 11.81% | 9.87% |
| Income Before Tax | 56.08% | 32.32% | 20.36% | 6.26% | 26.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.08% | 32.32% | 20.36% | 6.26% | 26.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.08% | 32.32% | 20.36% | 6.26% | 26.74% |
| EBIT | 47.42% | 28.52% | 24.79% | 11.81% | 9.87% |
| EBITDA | 44.09% | 25.35% | 21.84% | 12.46% | 13.40% |
| EPS Basic | 55.88% | 32.47% | 21.11% | 6.06% | 26.88% |
| Normalized Basic EPS | 51.28% | 33.33% | 19.64% | 7.32% | 2.50% |
| EPS Diluted | 55.88% | 32.47% | 21.11% | 6.06% | 26.88% |
| Normalized Diluted EPS | 51.28% | 33.33% | 19.64% | 7.32% | 2.50% |
| Average Basic Shares Outstanding | 0.02% | 0.00% | 0.00% | 0.00% | 0.28% |
| Average Diluted Shares Outstanding | 0.02% | 0.00% | 0.00% | 0.00% | 0.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |